We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Clovis Oncology’s Rubraca (Rucaparib) nearly halved the risk of disease progression in women with newly diagnosed advanced ovarian cancer following treatment combined with platinum-based chemotherapy. Read More
Roche has said its investigational monoclonal antibody, tiragolumab, combined with Tecentriq (atezolizumab) and chemotherapy did not meet the endpoints of overall survival or progression-free survival in a phase 3 study in patients with extensive-stage small-cell lung cancer (ES-SCLC). Read More
Sanofi and IGM Biosciences have signed an agreement to create, develop, manufacture and commercialize immunoglobulin M (IgM) antibody agonists against three oncology targets and three immunology/inflammation targets. Read More
Three antibodies directed at interleukins — inflammatory proteins associated with a number of skin disorders — posted positive phase 3 results and were touted at the annual meeting of the American Academy of Dermatology (AAD). Read More
The FDA has told MEI Pharma and Kyowa Kirin that they will need to provide more than results from a single-arm phase 2 study on their oral lymphoma drug candidate zandelisib to have it considered for the agency’s accelerated approval pathway. Read More
AstraZeneca’s checkpoint inhibitor Imfinzi (durvalumab) didn’t meet its primary endpoint of improving progression-free survival when compared with chemoradiotherapy (CRT) alone in the treatment of patients with locally advanced cervical cancer, the company said. Read More
Pfizer’s investigational once-a-day oral drug, etrasimod, has shown significant efficacy in a phase 3 study for the treatment of patients with ulcerative colitis. Read More
Argenx has released positive results from a late-stage trial of Vyvgart (efgartigimod alfa-fcab) for the subcutaneous treatment of patients with generalized myasthenia gravis. Read More
Moderna says that it’s expanding its messenger RNA (mRNA) vaccine pipeline to include mRNA-1230, a triple-combination respiratory vaccine candidate to protect against COVID-19, influenza and respiratory syncytial virus (RSV), and mRNA-1287, a vaccine candidate that will target four endemic human coronaviruses (HCoVs). Read More